AYAli Kaan Yildiz

Ali Kaan Yildiz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ali Kaan Yildiz has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The research landscape of single-port robotic partial nephrectomy: a bibliometric analysis

    by Arif Bedirhan Bayraktar, Ali Kaan Yıldız, Mustafa Baran Yılmaz, Fatih Kocamanoğlu, Ufuk Bozkurt

    The single-port robot-assisted partial nephrectomy (SP-RAPN) procedure has emerged as a minimally invasive approach for the surgical treatment of localized renal tumors. Although numerous publications have been reported, the scientific structure of this research field has not been systematically evaluated. This bibliometric study aimed to identify publication characteristics, key contributors, collaborations, and research themes related to SP-RAPN. Records were retrieved from the Web of Science Core Collection database. After excluding non-English studies, publications outside the Science Citation Index Expanded, non-original article types, and studies unrelated to the topic, 62 original articles published between 2009 and 2025 were included. Bibliometric mapping and visualization analyses were performed using Biblioshiny and VOSviewer. Publication output, citation trends, journal productivity, institutional contributions, country productivity, co-authorship networks, and keyword patterns were evaluated. A marked increase in publications was observed after 2021, with the highest annual output recorded in 2025 (n = 15). The Journal of Endourology and Journal of Robotic Surgery were the most productive journals, each publishing 12 articles. Yonsei University was the leading institution with 29 publications. The United States contributed the highest number of publications, citations, and authors. These findings demonstrate growing scientific interest in SP-RAPN. Although research activity remains concentrated in a limited number of countries and institutions, collaborative interactions appear to be increasing. Further multicenter and prospective studies are needed to better define the role of SP-RAPN in minimally invasive renal surgery.

  • Is perirenal fat an active player in renal cell carcinoma tumorigenesis? A radiologic-pathologic correlation study

    by Yusuf Gökkurt, Tolga Karakan, Buğra Bilge Keseroğlu, Veysel Bayburtluoğlu, Demirhan Örsan Demir, Ali Kaan Yıldız, Turgay Kaçan

  • Open Access

    Mapping the evolution and research landscape of Retzius-sparing robot-assisted radical prostatectomy: a bibliometric analysis

    by Çağrı Öktem, Ali Kaan Yıldız, Yusuf Gökkurt, Arif Bedirhan Bayraktar, Ahmet Varan, Ömer Furkan Erbay

    This study aimed to analyze the scientific literature on Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) using bibliometric methods to identify temporal trends in publication output, major research themes, and the structural characteristics of the field. Original research articles published in English between 2011 and 2025, indexed in the Web of Science Core Collection database and included in the Science Citation Index Expanded (SCI-E), were analyzed. Publications retrieved through a predefined search strategy were evaluated in terms of annual scientific production, citation indicators, journal distribution, highly influential studies, and author and keyword networks. Bibliometric analyses and visualizations were performed using Biblioshiny (Bibliometrix R package) and VOSviewer. A total of 93 original research articles met the inclusion criteria. Annual publication output increased markedly after 2017, reaching a peak in 2023. Journal of Robotic Surgery emerged as the most productive journal ( n = 12), whereas European Urology, Journal of Urology, and BJU International demonstrated the highest impact and visibility. Italy ( n = 24), the United States ( n = 21), and China ( n = 17) were identified as the leading contributors to scientific output. Citation analyses showed that the intellectual foundation of the field is centered on a limited number of seminal studies. Keyword and network analyses revealed a predominant focus on functional outcomes, refinement of surgical techniques, and learning curve–related themes. Overall, the RS-RARP literature represents an increasingly mature and expanding research domain, and these findings provide a quantitative overview of its current structure while offering guidance for future clinical and methodological investigations.


  • Evaluation of Multifocal Positive Surgical Margin Predictors and Mapping of Positive Surgical Margin Locations in Robot-assisted Radical Prostatectomy

    by Ali Kaan Yildiz, Huseyin Gultekin, Turgay Kacan, Demirhan Orsan Demir, Yusuf Gokkurt, Omer Furkan Erbay, Sedat Tastemur, Bugra Bilge Keseroglu, Tolga Karakan


  • Comparison of Spinal and General Anesthesia Outcomes in Geriatric Patients Undergoing Retrograde Intrarenal Surgery

    by Demirhan Örsan Demir, Salih Bürlukkara, Turgay Kaçan, Ali Kaan Yıldız, Yusuf Gökkurt, Ömer Furkan Erbay, Tolga Karakan

    Objective: This study aims to investigate the feasibility of spinal anesthesia (SA) in retrograde intrarenal surgery (RIRS) among patients aged over 65 years, and to compare the effectiveness of spinal and general anesthesia (GA) techniques on postoperative pain. Material and Methods: A retrospective analysis was conducted on 281 patients who underwent RIRS. Patients were divided into two groups: those who received SA (Group 1) and those who received GA (Group 2). Perioperative and postoperative outcomes of RIRS were compared between the groups. Additionally, postoperative pain levels in both the early and late periods were assessed using the Visual Analog Scale (VAS). Results: Group 1, which received SA, consisted of 166 patients, while Group 2, which received GA, included 115 patients. There was no statistically significant difference between the two groups in the demographic data and stone characteristics. The complication rates, classified according to the modified Clavien-Dindo system, were comparable between the two anesthesia techniques. The mean early postoperative VAS score was 2.26 ± 0.99 in Group 1 and 3.58 ± 1.13 in Group 2, with the difference being statistically significant (p < 0.001). However, there was no statistically significant difference in late postoperative VAS scores between the groups (p = 0.362). Postoperative analgesic requirement was observed in 10.24% of patients in Group 1, compared to 27.82% in Group 2, and this difference was statistically significant (p < 0.001). Conclusion: SA may be a viable alternative to GA in geriatric patients undergoing RIRS, as it provides favorable outcomes in postoperative pain control and may protect patients from certain potential morbidities associated with GA.

  • Two different protocols in single, immediate, postoperative intravesical chemotherapy after transurethral resection in suspected, low-risk, non-muscle-invasive bladder cancer

    by Ali Kaan Yildiz, Arif Bayraktar, Turgay Kacan, Demirhan Orsan Demir, Yusuf Gokkurt, Omer Furkan Erbay, Bugra Bilge Keseroglu, Berat Cem Ozgur, Omer Gokhan Doluoglu, Tolga Karakan

    Purpose To evaluate different protocols to increase the efficacy and reliability of single, immediate intravesical postoperative chemotherapy (IPOC) after transurethral bladder tumour resection (TURBT). Methods A retrospective evaluation was made of 104 patients, who underwent TURBT between October 2020 and October 2022, and were subsequently administered IPOC. The patients were examined in two groups as infusion IPOC (n:50) and bolus IPOC (n:54). In the infusion IPOC group, 50 mg epirubicin in 100 mL saline was administered intravesically in 30 min as an infusion with gravity. In the bolus IPOC group, 50 mg epirubicin in 50 mL saline was administered intravesically as a bolus with a catheter-type syringe. Preoperative information was recorded, including age, gender, body mass index (BMI), ASA score, smoking status, primary tumour, and previous IPOC, and postoperative information, including number, size, stage, and grade of tumour, the presence of detrusor muscle in the specimen, prognostic risk group, and second TURB. The two groups were compared with respect to dysuria, urgency, pain (VAS score), IPOC discontinuation, tumour recurrence rate, and recurrence-free survival (RFS). Results No statistically significant difference was determined between the groups with respect to age, gender, BMI, ASA score, smoking status, presence of primary tumour, number and size of tumours, the presence of detrusor muscle in the specimen, stage and grade of tumour, prognostic risk group, second TURB, and previous IPOC (p > 0.05 for all). The VAS score for pain/bladder irritation was determined to be statistically significantly lower at 2.3 ± 1.8 in the infusion IPOC group compared to 3.1 ± 2.2 in the bolus IPOC group (p = 0.01). The discontinuation rate of 10.0% was statistically significantly lower in the infusion IPOC group compared to the 25.9% rate determined in the bolus group (p = 0.04). Although the RFS rate was higher in the infusion IPOC group in all the NMIBC patients (p = 0.4) and in the low-risk NMIBC subgroup (p = 0.1), no significant difference was found. In the low-risk NMIBC, the 3-month recurrence rate was 3.3% in the infusion IPOC group and 20.5% in the bolus group, and thus the infusion protocol was observed to have significantly reduced early recurrence (p = 0.04). Conclusion The results of this study showed that an infusion IPOC protocol demonstrated reliability, efficacy, and applicability, which decreased bladder irrigation and treatment discontinuation rates while also reducing early recurrence.

  • Antikoagülan Ve Antiagregan İlaç Kullanan Hastalarda Radikal Sistektomi ve Radikal Prostatektomi Operasyonu: Preop Hasta Hazırlık ve Postop Takip Süreci

    by Ali Kaan Yıldız

    Ürolojik hastaların çoğu tıbbi komorbiditelere sahiptir. Ürologlar sıklıkla atriyal fibrilasyon, mekanik kalp kapakçıkları veya koroner arter hastalığının tedavisi için antikoagülan veya antiplatelet tedavisi gören hastalarla karşılaşırlar. Bu tedavilerin kesilmesini içeren perioperatif yönetim dönemi zorlu ve komplikasyonlara açık olabilir. Protez kapaklar, atriyal fibrilasyon ve koroner arter stentleri gibi belirli tıbbi durumların tedavisi için kullanılan antikoagülan ve antiplatelet ajanların ameliyat öncesi yönetimi, dahiliye uzmanı veya kardiyolog ile birlikte yapılmalıdır. Elektif ürolojik cerrahinin metal stentler için en az 30 gün, ilaç salınımlı stentler içinse mümkünse 1 yıldan daha uzun süre ertelenmesi önerilmiştir. Ancak onkolojik prosedürlere göre bu durum değerlendirilmelidir. Radikal prostatektomi ve radikal sistektomi ürolojinin yüksek kanama riski olan ve elektif olarak değerlendirilmeyen prosedürleridir. Radikal prostatektomi ve radikal sistektomide mevcut bilimsel kanıtlar, arteriyel tromboz gelişme riski daha yüksek olan hastalarda perioperatif antiplatelet tedavinin sürdürülmesi olasılığını ortaya koymaktadır, çünkü faydaları kanama riskinden daha ağır basmaktadır. Özellikle minimal invaziv cerrahinin gelişmesi ile birlikte antiplatelet tedavi devam ederken opere edilen hastalarda intraoperatif ve postoperatif komplikasyonlarda artış görülmemiştir. Antikoagülan tedavide ise düşük molekül ağırlıklı heparin ile köprüleme tedavisi kullanılmasına rağmen doz bağımlı olarak kanama komplikasyonlarının dikkatle izlenmesi gerekmektedir. Cerrahi sonrası dönemde ise dördüncü günde kanama komplikasyonu olasılığının oldukça azalmasından dolayı eğer antiplatelet veya antikoagülan tedavi kesilmişse başlanabileceği önerisi yapılmıştır. Most urologic patients have medical comorbidities. Urologists often encounter patients on anticoagulant or antiplatelet therapy for the treatment of atrial fibrillation, mechanical heart valves or coronary artery disease. The perioperative management period, including discontinuation of these therapies, can be challenging and prone to complications. Preoperative management of anticoagulants and antiplatelet agents used for the treatment of certain medical conditions, such as prosthetic valves, atrial fibrillation and coronary artery stents, should be done in conjunction with an internist or cardiologist. It has been recommended to postpone elective urologic surgery for at least 30 days for metal stents and longer than 1 year for drug-eluting stents, if possible. However, this should be evaluated according to oncologic procedures. Radical prostatectomy and radical cystectomy are procedures in urology that have a high bleeding risk and are not considered elective. In radical prostatectomy and radical cystectomy, available scientific evidence suggests the possibility of continuing perioperative antiplatelet therapy in patients at higher risk of developing arterial thrombosis because the benefits outweigh the risk of bleeding. Especially with the development of minimally invasive surgery, there has been no increase in intraoperative and postoperative complications in patients operated on while continuing antiplatelet therapy. In anticoagulant therapy, although bridging therapy with low molecular weight heparin is used, dose-dependent bleeding complications should be carefully monitored. In the postoperative period, it has been suggested that antiplatelet or anticoagulant therapy can be started if antiplatelet or anticoagulant therapy has been discontinued, since the likelihood of bleeding complications is considerably reduced on the fourth postoperative day.

  • Open Access

    Ürolojik Girişimlerde Antikoagülan ve Antiagregan Kullanan Hastaların Yönetimi

    by İbrahim Keleş, Abdullah Gürel, Veli Mert Yazar, Mustafa Duran, Mehmet Enes Süzek, Pirsu Uğuz, Haşmet Sarıcı, Recep Uzun, Hayri Demirbaş, Sinem Yorgancı, et al.

    Kan Pıhtılaşma Mekanizması Mustafa DURAN Mehmet Enes SÜZEK Antikoagulan Ve Antiagregan İlaçların Tarihsel Gelişimi ve Etki Mekanizmaları Mustafa DURAN Pirsu UĞUZ Yeni Kuşak Antikoagülan ve Antiagregan İlaçlar ve Etki Mekanizmaları Haşmet SARICI Recep UZUN Antikoagülan ve Antiagregan İlaçların Genel Kullanım Endikasyonları Hayri DEMİRBAŞ Sinem YORGANCI Antikoagülan ve Antiagregan İlaçların Genel Komplikasyonları Ramazan GENCAN Abdullah GÜREL Antikoagülan ve Antiagregan İlaç Kullanan Hastaları Hangi Parametrelerle Takip Ediyoruz? Serkan GÖKASLAN Antiagregan İlaç Kullanan Hastalarda Sistoskopi ve Sistostomi Operasyonu: Hasta Hazırlık ve Takip Süreci Kutay TOPAL Kemal ULUSOY Antikoagülan-Antiagrean Kullanan Hastalarda Perkutan Nefrostomi Takılması; Preop Hasta Hazırlığı ve Hasta Takip Süreci Çiğdem ÖZER GÖKASLAN Antikoagülan ve Antiagregan İlaç Kullanan Hastalarda Temiz Aralıklı Kateterizasyon Kullanımı Ersin BEŞTAŞ Ümit DÜNDAR Antikogülan ve Antiagregan İlaç Kullanan Hastalarda Prostat Biyopsi İşlemi: Preop Hasta Hazırlık ve Postop Takip Süreci Veli Mert YAZAR Murat Cengizhan ATİK Antikoagülan ve Antiagregan İlaç Kullanan Hastalarda Transüretral Prostat Rezeksiyonu Operasyonu: Preoperatif Hasta Hazırlık ve Postoperatif Takip Süreci Demirhan Örsan DEMİR Antikoagülan ve Antiagregan İlaç Kullanan Hastalarda Holmium Laser Prostatektomi: Preop Hasta Hazırlık ve Postop Takip Süreci Arif DEMİRBAŞ Berkay EREN Antikoagülan ve Antiagregan İlaç Kullanan Hastalarda Tur-M Operasyonu: Preop Hasta Hazırlık ve Postop Takip Süreci Osman GERÇEK Melih ŞENKOL Antiagregan İlaç Kullanan Hastalarda Üreteroneskopi ve Retrograd İntrarenal Cerrahi Mustafa KARALAR Muhammed Ali ULUCAK Antikoagülan ve Antiagregan İlaç Kullanan Hastalarda Perkütan Nefrolitotomi (PNL) Operasyonu; Preop Hasta Hazırlıkve Postop Takip Süreci Turgay KAÇAN Antikoagülan Ve Antiagregan İlaç Kullanan Hastalarda Radikal Sistektomi ve Radikal Prostatektomi Operasyonu: Preop Hasta Hazırlık ve Postop Takip Süreci Ali Kaan YILDIZ Çoklu Antikoagülan ve Antiagregan Kullanan Koroner Stentli Hastalarda Ürolojik Operasyonların Genel Yönetimi Yusuf TAŞKIN Antikoagülan ve Antiagregan İlaç Kullanan Üroloji Hastalarında Anestezi Yönetimi Bilal Atilla BEZEN Antikoagülan ve Antitrombositik İlaç Kullanan Serebrovasküler Olay Yaşamış Hastalarda Ürolojik Operasyonların Yönetimi Abdullah GÜZEL Hilal Tuğba HOŞGELDİ Antikoagülan Antiagregan İlaç Kullanan ve Abdominopelvik Cerrahi Geçiren Üroloji Hastalarında Pulmoner Komplikasyonların Yönetimi Aydın BALCI Yeni Kuşak Antikoagülan ve Antiagreganların Komplikasyonlarının Vaka Sunumlarıyla İncelenmesi Mustafa Esat İNCE İbrahim KELEŞ

  • Open Access

    Prostat kanserinin tanısında beyaz küre, nötrofil, lenfosit ve trombosit sayılarının birbirine oranlarının prediktif rolü

    by Ali Kaan Yıldız, Turgay Kaçan, Aykut Koç, Berat Cem Özgür

    Amaç: Çalışma prostat spesifik antijeni (PSA) değerleri 4,0–20,0 ng/mL olan ve transrektal prostat biyopsisi yapılan hastalarda, prostat kanseri saptanmasında prediktif olabilecek hematolojik kriterleri araştırmayı hedeflemektedir. Gereç ve Yöntem: Ocak 2022 ile Aralık 2022 tarihleri arasında PSA değerleri 4,0–20,0 ng/mL olan, transrektal prostat biyopsisi yapılan hastaların biyopsi sonuçlarına göre retrospektif analiz yapıldı. Çalışmaya biyopsi sonucu prostat kanseri (26) ve benign prostat dokusu (41) tanısı alan, iki grupta toplam 67 hasta dahil edildi. Prostat kanserini predikte edebilecek toplam beyaz küre (WBC), nötrofil, lenfosit, trombosit sayısı ve birbirine oranları tek ve çok değişkenli analizler ile incelendi. Ayrıca eğri altında kalan alanı hesaplamak ve parametrelerin tanısal performansını değerlendirmek için ROC eğrileri üretildi ve en iyi limit değeri belirlendi. Bulgular: WBC/nötrofil ve trombosit/nötrofil oranı prostat kanseri grubunda anlamlı yüksek (sırasıyla p=0.004 ve p=0.001), nötrofil/lenfosit oranı prostat kanseri grubunda anlamlı düşük olarak saptandı (p=0.048). Anlamlı fark bulunan bu faktörler ile yapılan çok değişkenli lojistik regresyon analizinde, WBC/nötrofil (odds ratio [OR] 0.00, %95 GA: 0.00–0.29; p = 0.001), nötrofil/lenfosit (OR 0.12, %95 GA: 0.03-0.48; p = 0.003) ve trombosit/nötrofil (OR 0.94, %95 GA: 0.89-0.98; p = 0.013) prostat kanseri ile ilişkiliydi. ROC analizinde WBC/nötrofil için AUC 0.712 (%95 CI 0.582-0.843) bulundu. En iyi limit değeri 1.69 olarak belirlendi ve ≥ 1.69 olan değerler için sensivite 0.69, spesifite 0.68 ve tanısal verimlilik 0.68 saptandı. ROC analizinde trombosit/nötrofil için AUC 0.705 (%95 CI 0.573-0.838) bulundu. En iyi limit değeri 58.4 olarak belirlendi ve ≥ 58.4 olan değerler için sensivite 0.69, spesifite 0.73 ve tanısal verimlilik 0.71 saptandı. Sonuç: PSA’sı 4,0–20,0 ng/mL olan hastalarda WBC/nötrofil ve trombosit/nötrofil oranlarının prostat biyopsisinde kanser saptanmasını öngörebilecek basit, klinikte rutin uygulanan ve başarılı parametreler olabileceği gösterilmiştir.